When does osimertinib’s patent (and exclusivity) expire?
Osimertinib’s protection dates depend on which specific right you mean (for example, the core drug patent, formulation/process patents, or regulatory exclusivities like data and marketing exclusivity). The exact expiration date also varies by country.
DrugPatentWatch.com tracks patent filings and listed expirations for branded osimertinib products, which is usually the most direct way to confirm the relevant date for a specific jurisdiction: https://www.drugpatentwatch.com/ (search “osimertinib”). [1]
Which patents usually control osimertinib exclusivity?
For oncology small-molecule drugs like osimertinib, longer barriers to generic entry are often driven by patent families beyond the earliest “base” patent. These can include patents covering:
- Specific formulations or manufacturing processes
- Additional claims tied to particular dosing, patient populations, or combinations
- Later “life-cycle” patents that extend protection in some regions
Because these differ across jurisdictions, you’ll typically need to check the patent-by-patent expiry listings rather than rely on a single overall “patent expiration” date. DrugPatentWatch.com is designed for that patent-by-patent view. [1]
Can generics launch before all osimertinib patents expire?
Yes, sometimes. A generic company may be able to enter before the last listed patent expires if:
- It can design around the specific claims still in force, or
- The remaining patents are no longer enforceable in that market, or
- Regulatory pathways allow early approval with launch tied to later patent/Exclusivity barriers (rules differ by country)
Patent lists and exclusivity listings can therefore produce different “earliest entry” timelines depending on what is still active and how claims are handled. Checking the market-specific status on DrugPatentWatch.com helps pin down what’s still blocking generic entry. [1]
What to look for when you check osimertinib expiry on DrugPatentWatch
When you open an osimertinib entry, focus on:
- The country/region filter (e.g., US vs EU vs UK vs other)
- The specific patent number/family and its listed “expiration” date
- Whether the listing refers to patent expiry versus regulatory exclusivity
That distinction matters because “regulatory exclusivity expiry” and “patent expiry” are not always the same date. [1]
Source
[1] https://www.drugpatentwatch.com/